Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Atossa Therapeutics, Inc. (ATOS) since 2013 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Atossa Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1488039.
Total stock buying since 2013: $121,358.
Total stock sales since 2013: $714,543.
Total stock option exercises since 2013: $503,617.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 21,239 | $16,890 | 0 | $0 | 0 | $0 |
| 2023 | 0 | $0 | 50,000 | $32,500 | 0 | $0 |
| 2021 | 0 | $0 | 107,497 | $599,833 | 164,581 | $503,617 |
| 2017 | 12,500 | $4,950 | 0 | $0 | 0 | $0 |
| 2016 | 161,500 | $47,495 | 0 | $0 | 0 | $0 |
| 2015 | 5,400 | $7,020 | 0 | $0 | 0 | $0 |
| 2013 | 14,500 | $45,003 | 14,530 | $82,210 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-05 | 11,239 | $9,890 | 0 | $0 | 0 | $0 |
| 2025-03 | 10,000 | $7,000 | 0 | $0 | 0 | $0 |
| 2023-11 | 0 | $0 | 50,000 | $32,500 | 0 | $0 |
| 2021-07 | 0 | $0 | 107,497 | $599,833 | 164,581 | $503,617 |
| 2017-11 | 10,000 | $3,370 | 0 | $0 | 0 | $0 |
| 2017-04 | 2,500 | $1,580 | 0 | $0 | 0 | $0 |
| 2016-04 | 1,500 | $495 | 0 | $0 | 0 | $0 |
| 2016-03 | 30,000 | $11,100 | 0 | $0 | 0 | $0 |
| 2016-02 | 30,000 | $15,900 | 0 | $0 | 0 | $0 |
| 2016-01 | 100,000 | $20,000 | 0 | $0 | 0 | $0 |
| 2015-06 | 5,400 | $7,020 | 0 | $0 | 0 | $0 |
| 2013-11 | 10,000 | $25,790 | 0 | $0 | 0 | $0 |
| 2013-10 | 0 | $0 | 14,530 | $82,210 | 0 | $0 |
| 2013-05 | 500 | $2,745 | 0 | $0 | 0 | $0 |
| 2013-01 | 4,000 | $16,468 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-05-21 | Quay Steven C (President & CEO) | Buy | 11,239 | .88 | 9,890 |
| 2025-03-26 | Remmel H. Lawrence | Buy | 10,000 | .70 | 7,000 |
| 2023-11-15 | Weaver Gregory L (Former EVP, CFO, & Director) | Sale | 50,000 | .65 | 32,500 |
| 2021-07-02 | Weaver Gregory L (Director) | Sale | 107,497 | 5.58 | 599,833 |
| 2021-07-02 | Weaver Gregory L (Director) | Option Ex | 164,581 | 3.06 | 503,617 |
| 2017-11-15 | Guse Kyle (CFO, Gen Counsel and Secretary) | Buy | 10,000 | .34 | 3,370 |
| 2017-04-17 | Remmel H. Lawrence | Buy | 2,500 | .63 | 1,580 |
| 2016-04-01 | Remmel H. Lawrence | Buy | 1,500 | .33 | 495 |
| 2016-03-09 | Chen Shu-chih | Buy | 15,000 | .37 | 5,550 |
| 2016-03-09 | Quay Steven C (President & CEO) | Buy | 15,000 | .37 | 5,550 |
| 2016-02-16 | Chen Shu-chih | Buy | 15,000 | .53 | 7,950 |
| 2016-02-16 | Quay Steven C (President & CEO) | Buy | 15,000 | .53 | 7,950 |
| 2016-01-19 | Chen Shu-chih | Buy | 50,000 | .20 | 10,000 |
| 2016-01-19 | Quay Steven C (President & CEO) | Buy | 50,000 | .20 | 10,000 |
| 2015-06-12 | Remmel H. Lawrence | Buy | 5,400 | 1.30 | 7,020 |
| 2013-11-21 | Weaver Gregory L (Director) | Buy | 10,000 | 2.58 | 25,790 |
| 2013-10-01 | Chen Shu-chih (Chief Scientific Officer) | Sale | 7,265 | 5.66 | 41,105 |
| 2013-10-01 | Quay Steven C (CEO) | Sale | 7,265 | 5.66 | 41,105 |
| 2013-05-15 | Cross Alexander D (Director) | Buy | 500 | 5.49 | 2,745 |
| 2013-01-08 | Remmel H. Lawrence (Director) | Buy | 4,000 | 4.12 | 16,468 |
Insider trading activities including stock purchases, stock sales, and option exercises of ATOS listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Atossa Therapeutics, Inc. (symbol ATOS, CIK number 1488039) see the Securities and Exchange Commission (SEC) website.